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Abstract
Background: It is generally accepted that the energy resources of cancer cells rely on anaerobic metabolism or the
glycolytic system, even if they have sufficient oxygen. This is known as the Warburg effect. The cells skillfully survive
under hypoglycemic conditions when their circumstances change, which probably at least partly involves microRNA
(miRNA)-mediated regulation.
Methods: To determine how cancer cells exploit miRNA-mediated epigenetic mechanisms to survive in hypoglycemic
conditions, we used DNA microarray analysis to comprehensively and simultaneously compare the expression of
miRNAs and mRNAs in the HepG2 human hepatoma cell line and in cultured normal human hepatocytes.
Results: The hypoglycemic condition decreased the expression of miRNA-17-5p and -20a-5p in hepatoma cells and
consequently upregulated the expression of their target gene p21. These regulations were also confirmed by using
antisense inhibitors of these miRNAs. In addition to this change, the hypoglycemic condition led to upregulated
expression of heat shock proteins and increased resistance to caspase-3-induced apoptosis. However, we could not
identify miRNA-mediated regulations, despite using comprehensive detection. Several interesting genes were also
found to be upregulated in the hypoglycemic condition by the microarray analysis, probably because of responding to
this cellular stress.
Conclusion: These results suggest that cancer cells skillfully survive in hypoglycemic conditions, which frequently
occur in malignancies, and that some of the gene regulation of this process is manipulated by miRNAs.
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Background
The most common cause of death in Japan has been can-
cer since 1981, with half of Japanese people suffering from
cancer in their lifetime and one-third dying of cancer in
recent years (http://www.mhlw.go.jp/english/database/db-
hw/vs01.html). One reason for cancer development is gen-
omic mutations. Another reason is epigenetic alterations
that occur due to exposure to certain lifestyle factors, such
as unhealthy foods, smoking, and drinking, or certain en-
vironmental factors, such as ultraviolet light and air pollu-
tion. Unfortunately, we still have no definite solution for
cancer. Therefore, it is necessary to identify new thera-
peutic procedures by defining and exploiting the specific
characteristics of cancers. One specific cancer target might
lie in their metabolism.
The energy source of cells, including malignant cells, is
adenosine triphosphate (ATP). ATP is mainly produced
during the metabolism of glucose. Glucose metabolism in-
volves glycolysis, the tricarboxylic cycle, and oxidative
phosphorylation. The first two events occur in the cyto-
plasm, whereas the last event takes place in mitochon-
dria. In hypoxic conditions, the reaction always stops at
the stage of glycolysis. In 1921, it was reported that the
oxygen consumption of cancer tissues was higher than
that of normal tissues [1]. Accordingly, researchers have
since focused on the abnormal metabolic state of
cancer cells. Cancer cells cannot obtain enough oxygen
and nutrition because they proliferate so fast that their
nascent vasculature cannot keep up. This hypoxic
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condition facilitates the activation of a transcription
factor, hypoxia-induced factor-1, and the transcription
of glucose transporter and genes related to the glyco-
lytic system [2].
On the other hand, there have been observations that
the energy resources of cancer cells always depend on
anaerobic metabolism or the glycolytic system, even if
they have sufficient oxygen [3], namely, the Warburg
effect, with both glycolysis and cell proliferation increa-
sing in parallel [4]. These findings suggest a scenario
whereby an abnormal state of the glycolytic system may
be one of the mechanisms of carcinogenesis rather than
a scenario in which hypoxia makes cancer cells adopt a
hyperglycolytic condition. The glycolytic system has low
energy-producing efficiency and only two ATP mole-
cules are produced from one glucose molecule, in con-
trast to the 36 ATP molecules produced through
oxidative phosphorylation. This means that more glu-
cose is required for ATP production in the glycolytic
system. However, as mentioned above, cancer cells al-
ways live under hypoglycemic conditions in which they
themselves can obtain low levels of energy, and this con-
dition appears to be contradictive. There are several ex-
planations for this contradiction. One is that cancer cells
can produce nucleic acids and amino acids necessary for
their proliferation from an energy source other than
ATP [1, 5]. Another is that cancer cells would like to
avoid apoptosis without obtaining energy through mito-
chondria [6]. A final explanation is that cancer cells have
a tolerance for glucose insufficiency. Cancer cells may
skillfully live and proliferate in their hypoglycemic and
hypoxic conditions.
Epigenetic alterations during carcinogenesis have re-
ceived a great deal of attention. Recent investigations have
revealed an important regulatory role for microRNA
(miRNA) in epigenetic alterations in carcinogenesis and
malignant transformation. miRNAs are 21–23 base-paired
non-coding RNA that inhibit protein transcription by
binding to target mRNA. One-third of all human protein-
encoding genes is regulated by miRNA. In the present
study, we focused on changes in the miRNA expression of
liver cancer cells according to glucose concentration to in-
vestigate whether cancer cells adapt to altered glucose
conditions by altering mRNA expressions.
Methods
Cells and culture conditions
The HepG2 cell line was used as a cancer cell line and
was obtained from the American Type Culture Collec-
tion (Manassas, VA). In some of the experiments, long-
term primary cultured human hepatocytes (HepaRG®,
HEP220-MW24; Biopredic International, Saint Grégoire,
France) were used as normal human hepatocytes [7].
HepG2 cells were cultured as described previously [8] in
Dulbecco’s modified Eagle’s medium (DMEM; including
1000 mg/L of glucose) supplemented with 10 % fetal
bovine serum (FBS). The human hepatocyte culture was
maintained in long-term culture medium (MIL238-110 M)
according to the conditions recommended by the manu-
facturer. Cells were cultured in a humidified incubator with
5 % CO2 at 37 °C.
We established three glycemic conditions. The
hypoglycemic condition (200 mg/L glucose) comprised
20 mL DMEM (with 1000 mg/L glucose), 70 mL DMEM
(without glucose), and 10 mL FBS per 100 mL. The
normoglycemic condition (900 mg/L glucose) comprised
90 mL DMEM (with 1000 mg/L glucose) and 10 mL FBS
per 100 mL. The hyperglycemic condition (1800 mg/L
glucose) comprised 40 mL DMEM (with 4500 mg/L glu-
cose), 50 mL DMEM (without glucose), and 10 mL FBS
per 100 mL. The cells were cultured in 10-cm dishes
(AGC Techno Glass Co., Ltd., Tokyo, Japan).
Cell proliferation assay
Cell proliferation was assayed using a CellTiter 96®
AQueous One Solution Cell Proliferation Assay (Pro-
mega KK, Tokyo, Japan). Cells were cultured in 96-well
plates with 100 μL culture medium per well. Twenty
microliters of CellTiter 96® AQueous One Solution Re-
agent was added to each well and the plates were incu-
bated in a 5 % CO2 humidified incubator at 37 °C for
1 h. The absorbance at 490 nm was then measured with
a microplate reader. The background was measured
using culture medium alone without cells.
Protein extraction and western blotting
Proteins were purified according to the method described
previously [8] and their concentrations were measured
with a BCA™ Protein Assay kit (Pierce Biotechnology
Inc.). They were stored at −80 °C until use.
Proteins were separated on NuPAGE® 4–12 % Bis-Tris
Gels (Life Technologies Japan Ltd., Tokyo, Japan) and
transferred to iBlot™ Gel Transfer Stacks Nitrocellulose,
Mini using iBlot™ (Life Technologies Japan Ltd.). The
membranes were washed with PBS-T (0.01 M phosphate-
buffered saline [PBS], 0.1 % Tween 20) and blocked with
blocking buffer (0.01 M PBS, 0.02 % Tween 20, 5 %
blocking agent) on a shaker at room temperature for
1 h. After washing with PBS-T, the membranes were in-
cubated at 4 °C overnight with the following primary
antibodies diluted in PBS-T (0.1 % Tween 20): anti-
HSPA1B (ADI-SPA-810-D; 1:2000; StressGen), anti-
HSPA8 (sc-7298; 1:500; Santa Cruz Biotechnology, Inc.),
anti-p21 (sc-397; 1:5000; Santa Cruz Biotechnology, Inc.),
anti-c-Myc (sc-40; 1:500; Santa Cruz Biotechnology, Inc.),
or anti-actin (AC-40; 1:1000; Abcam). The membranes
were then washed with PBS-T and incubated at room
temperature for 1 h in secondary antibodies diluted in
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PBS-T (0.1 % Tween 20). After washing with PBS-T, the
membranes were reacted with ECL Select Western blot-
ting detection reagent (GE Healthcare UK Ltd., Little
Chalfont, Buckinghamshire, UK) and fluorescence was
detected.
RNA extraction and DNA microarray
RNAs (including miRNAs) were extracted using the mir-
Vana™ miRNA Isolation Kit (Life Technologies Japan Ltd.)
according to the recommendations of the manufacturer.
Microarray analysis was carried out using the Human
Oligo chip 25 K (ID QH0ZG35) by Toray Co. (http://
www.3d-gene.com/en/about/; Tokyo, Japan) as described
previously [9]. In brief, total RNA was amplified using an
Amino Allyl aRNA kit (Ambion). RNA from cells was la-
beled with Cy3 Mono-Reactive Dye (GE Healthcare Japan
Co., Tokyo, Japan), and control RNA was labeled with Cy5
Mono-Reactive Dye (GE Healthcare). After purification,
each 1-μg sample was mixed and hybridized at 37 °C for
16 h. After washing, the hybridized chip was scanned
using a 3D-Gene Scanner 3000 (Toray Co.). Background
was subtracted from the raw data and the values were
normalized according to a median Cy3/Cy5 ratio of 1.
Reverse transcription
Reverse transcription for miRNA was done with a Taq-
Man® MicroRNA Reverse Transcription Kit (Applied Bio-
systems). Two nanograms/microliter of RNA was added to
0.15 μL of 100 mM dNTPs (with dTTP), 1.00 μL of Multi-
Scribe™ Reverse Transcriptase (50 U/μL) (ThermoFisher
Scientific K. K., Kanagawa, Japan), 1.50 μL of 10 × Reverse
Transcription Buffer, 0.19 μL of RNase inhibitor (20 U/μL),
and 3.0 μL of RT primer; distilled water (dH2O) was added
to make 10 μL. Reverse transcription was performed using
a Master Cycler Gradient (Eppendorf) at 16 °C for 30 s,
42 °C for 30 min, and 85 °C for 5 s and the product was
stored at 4 °C. Reverse transcription for mRNA was per-
formed according to the previously described method [10].
Real-time polymerase chain reaction
The quantitative comparison of polymerase chain reac-
tion (qPCR) products was performed by real-time PCR.
qPCR of miRNA (reaction mixture: 10.0 μL of 2 × Uni-
versal PCR Master Mix II [Applied Biosystems], 7.0 μL
of distilled water, 1.0 μL of TaqMan MicroRNA assay,
and 2.0 μL of reverse transcription product) was done
with a CFX96™ Real-Time System (Bio-Rad) (at 95 °C for
10 min, followed by 45 cycles at 95 °C for 15 s and 60 °C
for 1 min). qPCR of mRNA was performed according to
the method described previously [10]. Primers used were as
follows: HSPA1B, F-TGGACTGTTG GGACTCAAGG
AC, R-GGAACGAAAC ACCCTTACAG TATCA; HSPA8,
F-TGCTGCTGCT ATTGCTTACG, R-TCAATAGTGA
GGATTGACAC ATCA; p21, F-GACTCTCAGG GTCGA
AAACG, R-GGATTAGGGC TTCCTCTTGG; and GAP
DH, F-CACCACCATG GAGAAGGC, R-GCTAAGCAGT
TGGTGGTGCA.
Measurement of caspase-3 activity
Caspase-3 activity was measured with ApoAlert® Caspase
Colorimetric Assay Kits (TaKaRa Clontech). Cell lysates
from 2 × 106 cells were centrifuged at 13,000 rpm at 4 °C
for 10 min and 50 μL of the supernatant was applied to
a 96-well microplate. Then, 50 μL of 2 × Reaction buffer/
Dtt Mix and 5 μL of caspase substrate (N-acetyl-Asp-Glu-
Val-Asp p-nitroanilide; DEVD-pNA) (TaKaRa Clontech)
were added and the samples were incubated at 37 °C for
1 h. A standard curve was created and the absorbance of
the sample was measured at 405 nm. The ratios of absor-
bance with and without H2O2 were calculated.
Cell cycle analysis
The cells were fixed with 100 % ethanol at −20 °C over-
night and reacted with 0.25 ng/mL of RNaseA at 37 °C
for 1 h. The cells were then tagged with propidium iodide
at room temperature for 30 min and analyzed with a flow
cytometer, as described previously [8].
Gene transfection
The hsa-miR-17-5p mirVana® miRNA inhibitor (Ambion®,
ThermoFisher Scientific K. K.) and hsa-miR-20a-5p mir-
Vana® miRNA inhibitor (Ambion®) were used to inhibit
the expression of miRNAs. They were mixed with Lipo-
fectamine® 3000 Reagent (ThermoFisher Scientific K. K.)
and were incubated at room temperature for 5 min. The
mixture was added to 70–90 % confluent HepG2 cells in
6-well culture dishes and the cells were incubated in 5 %
CO2 at 37 °C for 48 h.
Statistical analysis
Results are shown as the mean ± standard error (SE) and
data were analyzed by one-way analysis of variance and
multiple comparisons; the least significant difference
method was used if the difference was significant. All
comparisons are two-sided and a p-value <0.05 was con-
sidered significant. All statistical analyses were per-
formed using SPSS 22 for Windows (SPSS, IBM Japan,
Tokyo, Japan).
Results
The hypoglycemic but not hyperglycemic condition
decreased the cell proliferation of hepatoma cells
HepG2 cells were cultured in medium containing normal
glucose (900 mg/L), low glucose (200 mg/L), and high
glucose (1800 mg/L) concentrations for 1 week, and viable
cells were quantitatively assayed by the 3-(4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2- (4-sulfophe-
nyl)-2H-tetrazolium, inner salt (MTS) assay. The numbers
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of viable cells decreased in low glucose conditions but
were unchanged in high glucose conditions (Fig. 1).
Microarray analyses showed several possible linkages
between miRNA and mRNA expression
Comparative analyses of the expression of miRNAs (2555
genes) and mRNAs (24460 genes) of HepG2 cells and the
human hepatocytes after incubation for 1 week in different
culture conditions—high (1800 mg/L), normal (900 mg/L),
and low (200 mg/L) glucose concentrations—were per-
formed using 3D-Gene® (Toray Co.). In general, gene
expression was more markedly changed in HepG2 cells
than in normal HepaRG® human hepatocytes when cells
were cultured under different glucose concentrations
(Additional file 1: Figure S1). In the case of HepG2 cells,
the pattern of genes that showed more than a 2-fold
change under the hypoglycemic condition (200 mg/L) was
as follows: 232 showing an miRNA increase, 37 showing
an miRNA decrease, 1137 showing an mRNA increase,
and 2078 showing an mRNA decrease. In the case of
HepaRG® cells, the pattern of genes that showed more than
a 2-fold change under the hypoglycemic condition was as
follows: 13 showing a miRNA increase, 79 showing a
miRNA decrease, 345 showing an mRNA increase, and 89
showing an mRNA decrease. Table 1 shows these signifi-
cantly altered genes (the 10 genes showing the greatest in-
creases and decreases in HepG2 cells and in HepaRG®
cells) when the cell culture condition was changed from
900 mg/L to 200 mg/L glucose. Different genes were found
to increase or decrease between HepG2 and HepaRG® cells.
When the cell culture condition was changed from nor-
mal (900 mg/L) to hyperglycemic (1800 mg/L), miRNA
and mRNA expressions were also changed but the num-
ber of miRNAs and mRNAs affected was lower than that
seen after the hypoglycemic change (Additional file 1:
Figure S1). In HepG2 and HepaRG® cells, 79 and 9 miR-
NAs and 1011 and 335 mRNAs, respectively, showed a
more than 2-fold increase in response to a change to the
hyperglycemic condition (1800 mg/L). In HepG2 and
HepaRG® cells, 15 and 81 miRNAs and 620 and 153
mRNAs, respectively, showed a more than 2-fold decrease
in response to a change to the hyperglycemic condition.
The 10 genes showing the greatest increase and the 10
genes showing the greatest decrease when the cell culture
condition was changed from 900 mg/L to 1800 mg/L glu-
cose concentration are shown in the Additional file 2:
Table S1. The genes found to be increasing or decreasing
were also different between HepG2 and HepaRG® cells, as
for the change to the hypoglycemic condition.
We searched miRNA databases (http://mirdb.org/miRDB/
and http://www.targetscan.org) to identify expected gene
regulators. In HepG2 cells under hypoglycemic conditions,
we found a significant decrease in the expression of
miR-17-5p, −18a-5p, −19a-3p, and -20a-5p, which to-
gether comprise the functional miR-17/92 cluster (18).
We found one candidate for a regulatory relationship
between miRNA and mRNA expression, namely, heat
a b
c d
Fig. 1 Cultured HepG2 cells after incubation with various concentrations of glucose. Representative microphotographs of HepG2 cells cultured with 200
(a), 900 (b), and 1800 (c) mg/L of glucose for 1 week (original magnification × 20). The results of the MTS assay are shown in (d). HepG2 cells were cultured
with three different glucose concentrations (200, 900, and 1800 mg/L) for 1 week and cell number was measured with the MTS assay. There were fewer
HepG2 cells when cells were cultured in the hypoglycemic condition (200 mg/L) than in the normoglycemic condition (900 mg/L). ***p< 0.001
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Table 1 Microarray analysis results from HepG2 and HepaRG® cells
miRNA Glucose (mg/L) Ratio mRNA Glucose (mg/L) Ratio
900 200 900 200
A-1) The 10 genes showing the great increase in HepG2 cells
2003miR-150-3p 35.2 185.4 5.27 IFI27 26 281 10.81
miR-575 97.3 471.9 4.85 HSPA1B 287 2009 7.00
miR-3158-5p 41.1 173.7 4.23 IF16 22 144 6.55
miR-593-5p 27.8 112.6 4.05 CMBL 53 296 5.58
miR-1273e 41.2 164.3 3.99 SULF2 19 106 5.58
miR-6724-5p 1080.5 4078.7 3.77 CYP1A1 25 135 5.40
miR-671-5p 71.8 265.8 3.70 CAPN3 54 286 5.30
miR-4725-3p 141.9 487.1 3.42 DDB2 125 624 4.99
miR-8059 154.7 520.5 3.36 NT5DC4 24 119 4.96
miR-373-5p 44.5 144.6 3.25 LY96 160 792 4.95
A-2) The 10 genes showing the great decrease in HepG2 cells
miR-106a-5p 2174.7 1259.1 0.58 KIF21A 338 38 0.11
miR-15b-5p 243.3 148.8 0.61 SLCC7A11 273 33 0.12
miR-93-5p 684.5 421.1 0.62 ANKRD12 354 48 0.14
miR-20a-5p 1793.2 1219.7 0.68 GOLGA4 249 36 0.14
miR-17-5p 2144.4 1479.7 0.69 TNKS2 104 15 0.14
miR-455-3p 213.3 147.6 0.69 MMD 232 34 0.15
miR-16-5p 1133.7 792.8 0.70 SLC38A2 1313 202 0.15
miR-19a-3p 381.5 274.8 0.72 ARHGAP18 356 55 0.15
miR-18a-5p 306.7 220.9 0.72 ZNF12 116 19 0.16
miR-26b-5p 966.8 775.9 0.78 ATP2B1 244 40 0.16
B-1) The 10 genes showing the great increase in HepaRG® cells
miR-6829-5p 44.8 102.3 2.28 RGS9 129 280 2.17
miR-3679-5p 164.8 225.4 1.37 SLC4A7 113 226 2.00
miR-4675 177.4 234.8 1.32 MY09A 56 112 2.00
miR-6726-5p 87.3 104.7 1.20 CAMSAP1L1 62 123 1.98
miR-6799-5p 203.8 238.3 1.17 SDCCAG1 101 197 1.95
miR-6803-5p 737.2 818.5 1.11 BCL9L 250 483 1.93
miR-6858-5p 181.7 197.9 1.09 PPHLN1 266 497 1.87
miR-6779-5p 148.0 148.0 1.07 BAT2L 350 652 1.86
miR-6721-5p 150.4 150.4 1.06 ZNF783 77 142 1.84
miR-6819-5p 198.4 198.4 1.05 RRAD 74 136 1.84
B-2) The 10 genes showing the great decrease in HepaRG® cells
miR-26b-5p 205.5 85.9 0.42 ESD 252 124 0.49
miR-191-5p 102 44.5 0.44 HMGCS1 4950 2531 0.51
let-7 g-5p 212.4 101.1 0.48 DDIT3 205 109 0.53
miR-19b-3p 290.3 138.3 0.48 MAP3K4 107 57 0.53
miR-20b-5p 103.1 50.0 0.48 GPR125 121 66 0.55
miR-1246 4912.0 2388.6 0.49 SMAD1 101 55 0.54
let-7e-5p 215.6 107.8 0.50 WBSCR1 305 167 0.55
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shock protein A1B (HSPA1B), which is possibly regu-
lated by miR-15b-5p and miR-16-5p. HSPA1B belongs
to the 70-kDa heat shock protein (HSP70) family and is
induced by some stresses such as heat or hypoxia to in-
hibit cellular apoptosis [11–13]. HSPA1B also plays a
role as a chaperone, which keeps intracellular proteins
in their normal state [14, 15]. On the other hand, in
normal hepatocytes, HSPA1B expression was not sig-
nificantly changed, although the expression of miR-15b-
5p and miR-16-5p decreased under hypoglycemic con-
ditions (Table 2). HSPA8 also belongs to the HSP70
family and inhibits apoptosis [12, 13], and this gene is
targeted by miR-17-5p and miR-20a-5p, among the
miRNAs shown in Table 1. Although expression of
these two miRNAs greatly decreased (by about half ),
the expression of HSPA8 was increased only about
1.17-fold in the hypoglycemic condition in HepG2 cells,
and its expression was not changed in normal hepato-
cytes (Table 2). Given these results, we did not assess
the changes in the expression of the mRNAs in the
HepaRG® cells.
miR-17-5p and miR-20a-5p decrease the expression of
cyclin-dependent kinase inhibitor 1A (CDKN1A) [16],
whose expression was increased about 2.45-fold in the
hypoglycemic condition in HepG2 cells, although its ex-
pression was not changed in normal hepatocytes HepaRG®
cells (Table 2) [16]. CDKN1A is the same as p21 and
inhibits the G1/S checkpoint of the cell cycle, stopping
cells in the G1 phase [17–19]. In response to these find-
ings, we examined whether the expression of HSPA1B and
miR-15b-5p/16-5p and that of HSPA8/p21 and miR-17-
5p/20a-5p were coupled.
As shown in Table 2, the baseline expression level of
HSPA1B and HSPA8 was much higher in HepG2 cells than
in HepaRG® cells (287 vs. 139 and 9925 vs. 5386, respect-
ively), suggesting that the baseline resistance to stresses
might be much stronger in HepG2 cells than in HepaRG®
cells. The baseline expression level of CDKN1A was much
higher in HepaRG® cells than in HepG2 cells (1439 vs.
291), suggesting that there might be more S phase cells in
HepaRG® cultures.
Linkage between the expression of HSPA1B and the
expression of miR-15b-5p and miR-16-5p
We confirmed the relationship between the expression of
miR15b-5p/16-5p and HSPA1B. Both protein and mRNA
expression levels of HSPA1B were found to increase in the
low glucose condition using qPCR and western blotting
(Fig. 2a), but the expression levels of miR-15b-5p and −16-
5p were not changed (Fig. 2b). We could not confirm the
microarray data in the low glucose condition in the case
of miR-15b-5p and −16-5p.
Linkage between the target gene expression of the miR-17/
92 cluster and c-Myc expression
Real-time PCR was performed to confirm the decrease in
the expression of the miR-17/92 cluster in the low glucose
condition. The expression of miR-17-5p, −18a-5p, −19a-
3p, and -20a-5p was significantly decreased in the low glu-
cose condition and was significantly increased in the high
glucose condition (Fig. 3a).
Because HSPA8 and p21 are reported to be targets of
miR-17/92 (http://mirdb.org/miRDB/ and http://www.tar
getscan.org), we examined their expressions in the low
glucose condition, finding an increase in the mRNA and
protein expressions of HSPA8 and p21 (Fig. 3b, c). We
Table 1 Microarray analysis results from HepG2 and HepaRG® cells (Continued)
miR-100-5p 208.6 104.3 0.50 PGM3 132 72 0.55
miR-148a-3p 256.5 130.0 0.51 THRSP 442 253 0.57
miR-122-3p 215.8 112.9 0.52 PSMB6 1013 600 0.59
The result of microarray analysis of differently expressed miRNAs and mRNAs when HepG2 and HepaRG® cells were cultured in different glucose concentrations.
Genes whose expression was greatly altered after the incubation of cells with two different concentrations of glucose, 900 mg/dL and 200 mg/dL, are shown. The
10 genes showing the great increase (A-1, B-1) and the 10 genes showing the greatest decrease (A-2, B-2) from 900 mg/L to 200 mg/L glucose are shown. The dif-
ference in the gene expression in HepG2 cells is shown in Table 1A, whereas that of HepaRG cells® is shown in Table 1B
Table 2 The change in the expression of the possibly linked
genes in HepG2 cells and normal HepaRG® hepatocytes detected
by microarray analyses (200 mg/L glucose vs 900 mg/L)
miRNA Glucose (mg/L) Ratio mRNA Glucose (mg/L) Ratio
900 200 900 200
a) HepaRG® (normal hepatocytes)
miR-15b-5p 51 25.1 0.49 HSPA1B 139 140 1.01
miR-16-5p 325.5 209.2 0.64 HSPA8 5386 5148 0.96
miR-17-5p 162.9 96.8 0.59 CDKN1A 1439 1457 1.01
miR-20a-5p 122.7 76.5 0.62
b) HepG2
miR-15b-5p 243.3 148.8 0.61 HSPA1B 287 2009 7.00
miR-16-5p 1133.7 792.8 0.70 HSPA8 9925 11574 1.17
miR-17-5p 2144.4 1479.7 0.69 CDKN1A 291 713 2.45
miR-20a-5p 1793.2 1219.7 0.68
The expression of HSPA1B mRNA was seen to be regulated by miR-15b-5p and
miR-16-5p, and this regulatory relationship was observed in the results of
microarray analyses in HepG2 cells; HSPA1B mRNA was not increased in
HepaRG® cells. HSPA8 transcription was not changed as much in either cell
type. The expression of CDKN1A mRNA was seen to be regulated by miR-17-5p
and miR-20a-5p, and this relationship was observed in HepG2 cells; CDKN1A
mRNA transcription did not change in HepaRG® cells
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next examined whether the glucose concentration affects
p21 expression by assessing the cell cycle with flow cy-
tometry (Fig. 3d). The hypoglycemic condition increased
p21 expression in HepG2 cells. In addition, the propor-
tion of cells in the G1 phase significantly increased,
whereas that of cells in the S and G2/M phases significantly
decreased under the hypoglycemic condition. When cells
were incubated under hyperglycemic conditions, no change
was noticed in the cell cycle phase.
Because c-Myc facilitates transcription of the miR-17/92
cluster, we examined c-Myc expression in the low glucose
condition using western blotting. However, its expression
was not altered (Additional file 3: Figure S2).
We next transfected the antisense RNA for miR-17-5 and
miR-20a-5p into HepG2 cells cultured under the normogly-
cemic condition. The expression levels of miR-17-5 and
miR-20a-5p were significantly suppressed by transfection of
the antisense inhibitors (Fig. 4a). However, the mRNA and
protein expression levels of HSPA8 were not altered
(Fig. 4b). On the other hand, the miR-17-5p inhibitor sig-
nificantly increased the transcription of p21 (Fig. 4b) and
protein expression was significantly inhibited when both
miR-17-5 and miR-20a-5p were inhibited with the antisense
RNA (Fig. 4b). The inhibition of both miR-17-5 and miR-
20a-5p increased the proportion of G1 phase cells and
decreased the proportion of S phase cells (Fig. 4c).
Increased expression of HSPA1B and HSPA8 in the
hypoglycemic condition confers resistance to H2O2-
induced apoptosis
The HSP family comprises anti-apoptotic factors that pro-
tect cells from various stresses by inhibiting caspase-3 activ-
ity. We examined whether cellular resistance to apoptosis
was enhanced by the increased expression of HSPA1B and
Fig. 2 The expression levels of miR-15b-5p and −16-5p and their target gene HSPA1B in HepG2 cells after incubation with various concentrations
of glucose. Cells were cultured with 200, 900, and 1800 mg/L of glucose for 1 week and qPCR and western blotting were performed to
quantitate the expression of miRNAs and their target mRNA and protein. a The expression levels of mRNA and protein of HSPA1B. The graph
shown under the western blotting images indicates the results of band densitometry analysis. b Expression levels of miR-15b-5p and miR-16-
5p. Error bars indicate the standard error (SE) of four different experiments. In the case of western blotting, the SE was calculated from the
densitometry data. *p < 0.05 (n = 4 each)
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HSPA8 in the low glucose condition. We added H2O2 (final
concentration, 0.8 mM) to induce oxidative stress in the
last 24 h of a 7-day culture of HepG2 cells under the differ-
ent glucose conditions. HepG2 cells cultured in the low
glucose condition were resistant to apoptotic stress due to
increased caspase-3 activity compared with cells cultured in
the normal glucose condition. On the other hand, HepG2
cells cultured in the high glucose concentration seemed to
show greater activation of caspase-3 (Fig. 5).
Discussion
Cancer cells mainly depend on the glycolysis system for
energy and have to adapt to environmental glucose con-
ditions. Here, we found evidence of miRNA-mediated
changes in human hepatoma-derived HepG2 cells in re-
sponse to environmental glucose concentrations. Under a
hypoglycemic condition, HepG2 cells became resistant to
apoptosis by increasing HSP expression and regulated the
cell cycle by changing p21 expression via miRNAs.
Because we wanted to examine whether some condi-
tions occur only in cancer cells, we used HepaRG® cells
as a control. As shown in Fig. 2, the change in the gene
expression of HepG2 cells according to the glucose con-
dition was much larger than that of normal hepatocytes.
We cannot evaluate whether the normal hepatocytes we
used worked well or not, but HepG2 cells were sensitive
to the glucose concentration in their surroundings,
which was reflected in the intracellular signaling. Fig. 1
shows that miRNA expression in HepG2 cells always in-
creased and that mRNA expression generally decreased
in the hypoglycemic condition. On the other hand, in
general, both the hypo- and hyperglycemic conditions
resulted in decreased miRNA expression in normal he-
patocytes, which increased mRNA expression. Thus,
cancer cells seemed more sensitive to glycemic condi-
tions and the gene expression was different to, or in
other words, the opposite of that of normal cells.
Among genes whose expression was upregulated in the
hypoglycemic condition, HSPA1B inhibits cellular apop-
tosis by inhibiting cytochrome c release from mitochon-
dria and downstream caspase-3 activation in HepG2 cells
[13]. HSPA1B might play an important role in HepG2 cells
because the expression of HSPA1B was maintained at rela-
tively high levels in HepG2 cells, even in the
normoglycemic condition, and its expression was not
changed in normal hepatocytes. We confirmed the in-
creased expression of this anti-apoptotic gene under the
hypoglycemic condition, but the levels of the anticipated
regulatory miRNAs, miR-15b and miR-16, did not
change, and other miRNA regulatory factors were not
found. Further investigation is necessary to clarify the
mechanism of this regulation.
HSPA8, which is a member of the HSP70 family, also
exerts an anti-apoptotic function [12, 13] by inhibiting
caspase-3 activation [13]. We confirmed that HepG2
cells under the hypoglycemic condition were resistant to
hydrogen peroxide-induced apoptosis, probably due to
upregulation of HSPA1B and HSPA8. HSPA8 expression,
as well as that of HSPA1B, was significantly increased in
HepG2 cells under the hypoglycemic condition and this
increase was not detected in normal hepatocytes. We in-
vestigated whether this increased expression was linked
with decreased expression of miR-17-5p and -20a-5p by
inhibiting these miRNAs with antisense RNA. However,
inhibition of miR-17-5p and -20a-5p did not alter the
HSPA8 expression, suggesting that there is no regulatory
correlation between HSPA8 and miR-17-5 and -20a-5p.
Although we did not identify the miRNA-related regula-
tory mechanism of the upregulation of HSPA expression,
a hypoglycemic condition seemed to render cancer cells
resistant to apoptotic stimulation.
One of the target genes of mir-17-5p and -20a-5p is
p21, which is a cell cycle regulator [16]. In HepG2 cells,
the expression of p21 was increased in the hypoglycemic
condition and knockdown of mir-17-5p and -20a-5p in-
creased the expression of p21. The change in the expres-
sion of p21 was minor in normal hepatocytes, suggesting
that cancer cells were more sensitive to the effect of low
glucose on the increase in p21 expression. p21 inacti-
vates the cyclin/cyclin-dependent kinase complex at the
G1/S checkpoint in the cell cycle and induces G1/S ar-
rest [17–19]. In HepG2 cells, the number of G1 phase
cells was increased in the hypoglycemic condition while
that of S and G2/M phase cells was decreased in re-
sponse to an increased expression of p21. These changes
in the cell cycle and p21 expression were also found in
cells transfected with the inhibitors for mir-17-5p and
-20a-5p. These results suggest that a decreased glucose
supply induces the cell cycle arrest of HepG2 cells in
(See figure on previous page.)
Fig. 3 The expression levels of the miR-17/92 cluster and its target genes, HSPA1B and P21, in cells after incubation with various concentrations
of glucose. a Cells were cultured with 200, 900, and 1800 mg/L of glucose for 1 week and the expression of the miR-17/92 cluster (miR17-5p,
miR-18a-5p, miR-19a-5p, and miR-20a-5p) was analyzed. The expression levels of the target genes of the miR-17/92 cluster (HSPA8 and P21) were
examined and the expression levels of mRNA (qPCR) and protein (western blotting) of HSPA8 (b) and P21 (c) were analyzed. The graph shown
under the western blotting images indicates the band densitometry results. The cell cycle was analyzed with a flow cytometer after the cells were
stained with propidium iodide (d). Error bars indicate the standard error (SE) of four different experiments. In the case of the western blotting, the
SE was calculated from the densitometry data. *p < 0.05, **p < 0.01, ***p < 0.001 (n = 4 each)
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response to decreased expression of mir-17-5p and -20a-
5p and the subsequent p21 increase. This metabolic
change in HepG2 cells may be an adaptive response of
cancer cells to a limited glucose supply in which the
cells reduce their energy consumption.
We found that changes in the glucose concentration
induced the expression of miR-17-5p, −18a, −19a, and
-20a-5p but we could not identify the factors regulating
these miRNAs. We considered that these miRNAs were
regulated as a cluster. One of the known regulatory fac-
tors of the miR-17/9 cluster is c-Myc but we could not
find any change in the expression of this protein. One
possible explanation is that there was a change in the
binding affinity between c-Myc and the miR-17/92 clus-
ter; another possible explanation involves the transcrip-
tion factor E2F, which is reported to regulate the
expression of the miR-17/92 cluster [20]. Further studies
are needed to identify the regulatory factors of the miR-
17/92 cluster that might link changes in the glucose con-
centration and miRNA expression.
We found using microarray analysis that interferon
alpha-inducible protein 27 (IFI27) and IFI6 were upregu-
lated in the hypoglycemic condition. These proteins are in-
duced by interferon stimulation. The expression of IFI27
and IFI6 is upregulated in epithelial malignancies, breast
cancer, and ovarian cancer [21–25], and their expression
may be abundant in cancer cells. Interferon is a cytokine
that protects cells from viral infection and the upregulated
expression of IFI27 and IFI6 might be a protective response
of cancer cells to certain stresses, as well as to the upregula-
tion of HSP expression. Recently, Roulois et al. and Chiap-
pinelli et al. showed that DNA-demethylating agents can
induce a cell-autonomous immune active response by
stimulating the expression of dsRNA-containing endo-
genous retroviruses [26, 27]. We have also demonstrated
induction of an anti-viral response with the DNA methyla-
tion inhibitor 5-aza-2′-deoxycytidine in an intestinal tumor
organoid [28]. Thus, it seems that biological stresses induce
an anti-viral response and that this response might be
epigenetically regulated by DNA demethylation. Another
upregulated gene, lymphocyte antigen 96 (LY96), is also an
important factor in innate immunity, involved in the bin-
ding between lipopolysaccharide and toll-like receptor 4,
indicating that not only an anti-viral response, but also an
innate general immunity might be activated. Changes in
these immunological regulators triggered by a hypoglycemic
environment suggest that an accommodation of cancer cells
to the hypoglycemic condition allows them to resist attacks
from unfavorable foreign enemies, and it was also possible
that a hypoglycemic condition induced demethylation of
some genes. Further investigation of the epigenetic changes
of some specific genes may clarify these mechanisms. The
other genes found in the microarray analysis, such as CMBL
(a cysteine hydrolase of the dienelactone hydrolase family),
Sulf2 (a sulfatase), CAPN3 (a calcium-activated neutral
protease or a non-lysosomal intracellular cysteine protease),
and DDB2 (a DNA damage-binding protein), are enzymes
with various functions. These genes might also help
cancer cells to withstand several cellular stresses in the
hypoglycemic condition.
In the present study, we investigated how cancer cells
survive in the hypoglycemic condition, which frequently oc-
curs in vivo in patients with malignancies, regardless of
how cancer cells depend on glucose as an energy source.
Upregulated expression of p21 via miRNA-mediated epi-
genetic mechanisms and HSPs without regulation by
(See figure on previous page.)
Fig. 4 Effects of the hsa-miR-17-5p and hsa-miR-20a-5p mirVana® miRNA inhibitors. a Effects of miRNA inhibitors indicated by①-③ on the expression
levels of miR-17-5p and -20a-5p. b Effects of miRNA inhibitors indicated by①-④ on the expression of HDPA8 and p21. The expression of HDPA8 and
P21 were examined by both qPCR and western blotting. The graph shown under the western blotting images indicates the band densitometry
results. c Cell cycle analysis after the transfection of cells with miRNA inhibitors. The ratios of each cell cycle phase are shown as a bar graph. Blue color
indicates G1 phase, red color indicates S phase, and green color indicates the G2/M phase cell ratio. Error bars indicate the standard error (SE) of four
different experiments. In the case of western blotting, the SE was calculated from the densitometry data. *p < 0.05, **p < 0.01, ***p < 0.001 (n = 4 each)
Fig. 5 Caspase-3 activity induced by hydrogen peroxide in cells after
incubation with various concentrations of glucose. Cells were cultured
with 200, 900, and 1800 mg/L of glucose for 1 week and then 0.8 mM
of hydrogen peroxide was added to the culture. After incubation for
24 h, cells were collected and caspase-3 activity was measured with
absorbance at 405 nm. The ratios of the absorbance with and without
H2O2 were calculated. Error bars indicate the standard error (SE) of four
different experiments, as calculated from the data of the calculated
ratios. ***p < 0.001 (n = 4 each)
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miRNAs occurred in HepG2 cells but not in normal cells
under the hypoglycemic condition. Further investigation
with in vivo studies is required to validate these
phenomena.
Conclusions
HepG2 cells, a liver cancer cell line, seemed to adapt
themselves to the hypoglycemic condition, which always
occurs in human malignancies, and one of the mecha-
nisms of their adaptation involved miRNA-dependent
regulation. Our findings showed that HSPs were upregu-
lated by hypoglycemia in this cell line and that the cell
cycle was at least partly arrested via miRNA-dependent
p21 upregulation.
Additional files
Additional file 1: Figure S1. DNA microarray analysis after cells were
cultured with various concentrations of glucose. HepG2 and HepaRG®
cells were cultured with glucose concentrations of 200, 900, and
1800 mg/L for 1 week and the RNA extracted was analyzed by DNA array
(3D-Gene®, Toray; http://333.3d-gene.com/). Plots of mRNA expressions in
HepG2 and HepaRG® cells cultured with 900 mg/L (vertical axis) and
200 mg/L (horizontal axis) glucose (a and c, respectively). MicroRNA
expressions in HepG2 and HepaRG® cultured with 1800 mg/L (vertical
axis) and 900 mg/L (horizontal axis) glucose are plotted in b and d,
respectively. (PPTX 1966 kb)
Additional file 2: Table S1. Change in the expression of the indicated
genes between the hyperglycemic and normoglycemic conditions. Genes
whose expression was greatly altered after the incubation of cells with two
different concentrations of glucose, 900 mg/dL and 1800 mg/dL, are shown.
The 10 genes showing the greatest increase and the 10 genes showing the
greatest decrease from 900 mg/L to 1800 mg/L glucose are shown. The
difference in the gene expression in HepG2 cells is shown in Table 1a,
whereas that of HepaRG cells ® is shown in Table 1b. (DOCX 120 kb)
Additional file 3: Figure S2. c-Myc expression after incubation of cells
with various concentrations of glucose. Cells were cultured with 200, 900,
and 1800 mg/L of glucose for 1 week and the expression of c-Myc protein
was examined by Western blotting. The graph under Western blotting shows
the result of densitometry of bands. No significant change in this gene
expression was detected in different glucose concentrations. (PPTX 89 kb)
Abbreviations
ATP: Adenosine triphosphate; CDKN1A: Cyclin-dependent kinase inhibitor 1A;
DEVD-pNA: N-acetyl-Asp-Glu-Val-Asp p-nitroanilide; DMEM: Dulbecco’s
modified Eagle’s medium; FBS: Fetal bovine serum; IFI27: Interferon alpha-
inducible protein 27; LY96: Lymphocyte antigen 96; miRNA: microRNA;
MTS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H- tetrazolium, inner salt; PCR: Polymerase chain reaction;
qPCR: Quantitative polymerase chain reaction; SE: Standard error
Acknowledgements
We thank Toshihide Muramatsu for his assistance with cell cultures and
helpful suggestions throughout the experiments.
Funding
A grant from Japanese Society of Anti-Aging Medicine (H.S.) and a Grant-in-Aid
for Scientific Research C (15K09021) from the Japan Society for Promotion of
Science (H.S.)
Availability of data and materials
The dataset supporting the conclusions of this article is included within the article.
Authors’ contributions
SU and YM contributed to the data analyses, interpretation of results, and
approval of the manuscript; SY and MK contributed to data analyses,
interpretation of results, and approval of the manuscript; YS contributed to
the concept and design of the study, interpretation of results, and drafting
and approval of the manuscript; HS is responsible for the overall contents.
All authors have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Received: 2 June 2016 Accepted: 6 September 2016
References
1. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg
Effect: The Metabolic Requirements of Cell Proliferation. Science. 2009;
324(5930):1029–33.
2. Wigfield SM, Winter SC, Giatromanolaki A, Taylor J, Koukourakis ML, Harris
AL. PDK-1 regulates lactate production in hypoxia and is associated with
poor prognosis in head and neck squamous cancer. Br J Cancer. 2008;
98(12):1975–84.
3. Warburg O. On respiratory impairment in cancer cells. Science. 1956;
124(3215):269–70.
4. Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and
vulnerable to disruption. Nature. 2012;491(7424):364–73.
5. Potter VR. The biochemical approach to the cancer problem. Fed Proc.
1958;17(2):691–7.
6. Vaughn AE, Deshmukh M. Glucose metabolism inhibits apoptosis in
neurons and cancer cells by redox inactivation of cytochrome c. Nat Cell
Biol. 2008;10(12):1477–83.
7. Lanford RE, Carey KD, Estlack LE, Smith GC, Hay RV. Analysis of plasma
protein and lipoprotein synthesis in long-term primary cultures of baboon
hepatocytes maintained in serum-free medium. In Vitro Cell Dev Biol. 1989;
25(2):174–82.
8. Hibino S, Saito Y, Muramatsu T, Otani A, Kasai Y, Kimura M, Saito H.
Inhibitors of enhancer of zeste homolog 2 (EZH2) activate tumor-
suppressor microRNAs in human cancer cells. Oncogenesis. 2014;3:e104.
9. Sato A, Saito Y, Sugiyama K, Sakasegawa N, Muramatsu T, Fukuda S, Yoneya
M, Kimura M, Ebinuma H, Hibi T, et al. Suppressive effect of the histone
deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) on hepatitis C
virus replication. J Cell Biochem. 2013;114(9):1987–96.
10. Sugiyama K, Ebinuma H, Nakamoto N, Sakasegawa N, Murakami Y, Chu PS,
Usui S, Ishibashi Y, Wakayama Y, Taniki N, et al. Prominent steatosis with
hypermetabolism of the cell line permissive for years of infection with
hepatitis C virus. PLoS One. 2014;9(4):e94460.
11. Sliutz G, Karlseder J, Tempfer C, Orel L, Holzer G, Simon MM. Drug resistance
against gemcitabine and topotecan mediated by constitutive hsp70
overexpression in vitro: implication of quercetin as sensitiser in
chemotherapy. Br J Cancer. 1996;74(2):172–7.
12. Mosser DD, Morimoto RI. Molecular chaperones and the stress of
oncogenesis. Oncogene. 2004;23(16):2907–18.
13. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G. Heat shock
proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell
Cycle. 2006;5(22):2592–601.
14. Young JC, Agashe VR, Siegers K, Hartl FU. Pathways of chaperone-mediated
protein folding in the cytosol. Nat Rev Mol Cell Biol. 2004;5(10):781–91.
15. Daugaard M, Rohde M, Jaattela M. The heat shock protein 70 family: Highly
homologous proteins with overlapping and distinct functions. FEBS Lett.
2007;581(19):3702–10.
16. Wang Z, Liu M, Zhu H, Zhang W, He S, Hu C, Quan L, Bai J, Xu N. Suppression
of p21 by c-Myc through members of miR-17 family at the post-transcriptional
level. Int J Oncol. 2010;37(5):1315–21.
Ueki et al. BMC Cancer  (2016) 16:732 Page 12 of 13
17. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D,
Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53
tumor suppression. Cell. 1993;75(4):817–25.
18. Gu Y, Turck CW, Morgan DO. Inhibition of CDK2 activity in vivo by an
associated 20K regulatory subunit. Nature. 1993;366(6456):707–10.
19. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-
interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent
kinases. Cell. 1993;75(4):805–16.
20. Coller HA, Forman JJ, Legesse-Miller A. “Myc’ed messages”: myc induces
transcription of E2F1 while inhibiting its translation via a microRNA
polycistron. PLoS Genet. 2007;3(8):e146.
21. Suomela S, Cao L, Bowcock A, Saarialho-Kere U. Interferon alpha-inducible
protein 27 (IFI27) is upregulated in psoriatic skin and certain epithelial
cancers. J Invest Dermatol. 2004;122(3):717–21.
22. Rasmussen UB, Wolf C, Mattei MG, Chenard MP, Bellocq JP, Chambon P, Rio
MC, Basset P. Identification of a new interferon-alpha-inducible gene (p27)
on human chromosome 14q32 and its expression in breast carcinoma.
Cancer Res. 1993;53(17):4096–101.
23. Kim YS, Hwan JD, Bae S, Bae DH, Shick WA. Identification of differentially
expressed genes using an annealing control primer system in stage III
serous ovarian carcinoma. BMC Cancer. 2010;10:576.
24. Tsai MH, Cook JA, Chandramouli GV, DeGraff W, Yan H, Zhao S, Coleman
CN, Mitchell JB, Chuang EY. Gene expression profiling of breast, prostate,
and glioma cells following single versus fractionated doses of radiation.
Cancer Res. 2007;67(8):3845–52.
25. Bani MR, Nicoletti MI, Alkharouf NW, Ghilardi C, Petersen D, Erba E, Sausville EA,
Liu ET, Giavazzi R. Gene expression correlating with response to paclitaxel in
ovarian carcinoma xenografts. Mol Cancer Ther. 2004;3(2):111–21.
26. Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, Han H,
Liang G, Jones PA, Pugh TJ, et al. DNA-Demethylating Agents Target Colorectal
Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell. 2015;
162(5):961–73.
27. Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A,
Rote NS, Cope LM, Snyder A, et al. Inhibiting DNA Methylation Causes an
Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses.
Cell. 2015;162(5):974–86.
28. Saito Y, Nakaoka T, Sakai K, Muramatsu T, Toshimitsu K, Kimura M, Kanai T,
Sato T, Saito H. Inhibition of DNA Methylation Suppresses Intestinal Tumor
Organoids by Inducing an Anti-Viral Response. Sci Rep. 2016;6:25311.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ueki et al. BMC Cancer  (2016) 16:732 Page 13 of 13
